SAN FRANCISCO — The sumatriptan 3-mg subcutaneous auto-injector (Zembrace SymTouch, Promius Pharma) approved by the US Food and Drug Administration (FDA) for acute treatment of episodic migraine, with ...
The auto injector market represents a rapidly expanding segment within the global pharmaceutical delivery systems industry, driven by the increasing prevalence of chronic diseases and the growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback